Hepatic Steatosis (Fatty Liver) affects more than 30% of the global adult population. Under updated international clinical guidelines, it is classified as MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and its progressive inflammatory stage, MASH (Metabolic Dysfunction-Associated Steatohepatitis). Evaluating disease severity relies on non-invasive screening using the FIB-4 Index (combining Age, AST, ALT, and Platelet count) and Transient Elastography (FibroScan) to rule out advanced hepatic fibrosis.
Fatty liver disease is the most common chronic liver condition on Earth, affecting roughly 1 in 3 adults worldwide.
For years, it was called "Non-Alcoholic Fatty Liver Disease (NAFLD)." In 2023, international multi-society hepatology consensus officially updated the clinical terminology to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) to reflect its true biological root: systemic insulin resistance and cardiometabolic dysfunction.
How does simple fat accumulation progress to active inflammation and scarring, how do you calculate your FIB-4 fibrosis score, and how is hepatic steatosis staged non-invasively?
The New Nomenclature: MASLD vs. MASH#
The updated hepatology nomenclature provides clear diagnostic criteria:
| Previous Nomenclature | Updated Clinical Nomenclature | Clinical Definition & Criteria |
|---|---|---|
| NAFLD (Non-Alcoholic Fatty Liver Disease) | MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) | Hepatic steatosis (> 5% fat accumulation on imaging or histology) combined with at least 1 cardiometabolic risk factor (BMI ≥ 25, Prediabetes/A1c ≥ 5.7%, BP ≥ 130/85, High Triglycerides ≥ 150 mg/dL, or Low HDL). |
| NASH (Non-Alcoholic Steatohepatitis) | MASH (Metabolic Dysfunction-Associated Steatohepatitis) | Progressive, inflammatory subtype of MASLD characterized by active hepatocyte ballooning, lobular necroinflammation, and progressive collagen fibrosis. |
| MetALD | MetALD (Metabolic and Alcohol-Related Liver Disease) | Patients with MASLD who also consume moderate alcohol (140–350g/week for females, 210–420g/week for males). |
The Pathophysiology: From Fat Accumulation to Fibrosis#
[Systemic Insulin Resistance + High Fructose Intake]
│
▼
[Step 1: Simple Hepatic Steatosis (MASLD)]
- Intrahepatic triglyceride accumulation exceeding 5% of liver mass
│
▼
[Step 2: Lipotoxicity & Oxidative Stress (MASH)]
- Free fatty acids damage mitochondria; hepatocyte "ballooning"
│
▼
[Step 3: Stellate Cell Activation & Fibrogenesis]
- Hepatic stellate cells deposit cross-linked collagen scars (F1 ➔ F2 ➔ F3)
│
▼
[Step 4: Cirrhosis & End-Stage Liver Disease (F4)]
- Disrupted vascular architecture, portal hypertension, liver failure
- Intrahepatic Triglyceride Accumulation: Insulin resistance impairs adipose tissue lipolysis inhibition, flooding the portal vein with non-esterified fatty acids. Simultaneously, the liver accelerates de novo lipogenesis (especially from dietary fructose).
- Lipotoxicity & Hepatocyte Ballooning: When lipid storage capacity is overwhelmed, toxic lipid intermediates (ceramides and diacylglycerols) trigger mitochondrial free radical generation, killing hepatocytes.
- Hepatic Stellate Cell Activation: In response to chronic dying hepatocytes, resident stellate cells transform into myofibroblasts, laying down dense collagen scar tissue (fibrosis).
Non-Invasive Fibrosis Staging: The FIB-4 Index#
In modern outpatient medicine, liver biopsies are rarely needed for initial staging. The American Gastroenterological Association (AGA) recommends the FIB-4 (Fibrosis-4) Index as the primary screening tool:
FIB-4 = (Age [years] × AST [U/L]) / (Platelet Count [× 10^9/L] × √ALT [U/L])
| FIB-4 Score Range | Clinical Fibrosis Risk | Recommended Action |
|---|---|---|
| FIB-4 < 1.30 (or < 2.0 if age > 65) | Low Risk for Advanced Fibrosis (F0–F1) | 90%+ Negative Predictive Value: Advanced fibrosis is ruled out. Manage through lifestyle, diet, and annual primary care re-screening. |
| FIB-4 1.30 to 2.67 | Indeterminate Risk (F2) | Secondary testing required: Order Transient Elastography (FibroScan) or Enhanced Liver Fibrosis (ELF) blood test. |
| FIB-4 > 2.67 | High Risk for Advanced Fibrosis (F3–F4 / Cirrhosis) | Immediate Hepatology Referral: High probability of bridging fibrosis or cirrhosis; requires imaging for portal hypertension and hepatocellular carcinoma surveillance. |
Transient Elastography (FibroScan) Metrics#
When a patient undergoes a FibroScan, the ultrasound probe measures two distinct physical parameters:
- CAP Score (Controlled Attenuation Parameter in dB/m): Measures the degree of ultrasound attenuation caused by fat. Staged from S1 (mild > 248 dB/m) to S3 (severe > 280 dB/m).
- LSM (Liver Stiffness Measurement in kPa): Measures the speed of a physical shear wave through the liver. Staged from F0 (normal < 6.0 kPa) to F4 (cirrhosis > 12.5 kPa).
As liver fibrosis progresses to cirrhosis, blood flow through the portal vein backs up (portal hypertension). This causes the spleen to enlarge (splenomegaly), sequestering and destroying platelets. A dropping platelet count on a CBC is a critical warning sign of advancing liver disease.
To explore evidence-based protocols to reverse fatty liver naturally, read How to Lower Liver Enzymes & Reverse Fatty Liver.
Track Your Health & Liver Biomarkers with Meridian#
Monitoring your laboratory blood biomarkers over time gives you objective validation that your diet, exercise, and lifestyle habits are reversing hepatic steatosis and protecting liver architecture.
Meridian is an offline personal health vault for iPhone designed to give you complete ownership of your medical diagnostic data.
- Instant Lab Report Extraction: Take a photo or upload a PDF of your Comprehensive Metabolic Panel, Complete Blood Count, and lipid panels from Quest, Labcorp, or your clinic. Meridian extracts your biomarkers on-device using Apple VisionKit.
- Longitudinal Liver Trends: Track how your ALT, AST, and platelet counts evolve over years without uploading sensitive diagnostic records to third-party cloud servers.
- 100% On-Device & Private: Protected by hardware AES-256 encryption and FaceID. Zero cloud servers. Zero data tracking.
Take control of your liver health and medical privacy today. Download Meridian on the App Store and keep your diagnostic records organized, private, and secure.